Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00479128 · ClinicalTrials.gov registry record · Phase 1

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

A Phase 1 study of Solid Tumor and Urethral Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT00479128 is a Phase 1 study of Solid Tumor and Urethral Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00479128, a Phase 1 study of Solid Tumor and Urethral Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or other solid tumors.

Conditions Studied

Solid Tumor Urethral Cancer

Interventions

  • DRUG Doxorubicin
  • DRUG Gemcitabine
  • DRUG Bortezomib

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2006-09-28
Est. Completion 2026-09-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00479128

The ClinicalTrials.gov registry entry for NCT00479128 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (64% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Doxorubicin is the first listed.

NCT00479128 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00479128 about?

NCT00479128 is a clinical study titled "Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors". The goal of this clinical research study is to find the highest tolerable dose of Gemzar® (gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade® (bortezomib) in patients with urothelial cancer or other solid tumors.

What is the current status of trial NCT00479128?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2006-09-28. Estimated completion is 2026-09-30.

What conditions does trial NCT00479128 study?

This clinical trial studies the following conditions: Solid Tumor, Urethral Cancer.

What interventions are being tested in trial NCT00479128?

The interventions under investigation include: Doxorubicin (DRUG), Gemcitabine (DRUG), Bortezomib (DRUG).

Who is sponsoring clinical trial NCT00479128?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00479128 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor

All registered trials for this condition

Urethral Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.